Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Chen

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Journal of Psychosomatic Research|February 22, 2021
Trajectories of post-traumatic stress symptoms, anxiety, and depression in hospitalized COVID-19 patients: A one-month follow-upNoam Matalon, Shirel Dorman-Ilan, Ilanit Hasson-Ohayon, et al.
The Journal of General Virology|December 4, 2003
Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeysSridhar Pennathur, Aurelia A Haller, Mia MacPhail, et al.
Clinical Breast Cancer|January 31, 2025
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical TrialsDario Trapani, Qingchun Jin, Kathy D Miller, et al.
Child and Adolescent Psychiatry and Mental Health|June 20, 2024
Acute response to the October 7th hostage release: rapid development and evaluation of the novel ReSPOND protocol implementation within a children's hospitalNaama de la Fontaine, Tamar Silberg, Jörg M Fegert, et al.
The Journal of Infectious Diseases|March 5, 2005
A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancyDavid P Greenberg, Robert E Walker, Min-Shi Lee, et al.
British Journal of Haematology|September 4, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinibPreetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, et al.
The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2017
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized TherapyLeo Zhang, Krystle Nomie, Hui Zhang, et al.
Blood Advances|March 20, 2020
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCLPreetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Journal of Psychosomatic Research|February 22, 2021
Trajectories of post-traumatic stress symptoms, anxiety, and depression in hospitalized COVID-19 patients: A one-month follow-upNoam Matalon, Shirel Dorman-Ilan, Ilanit Hasson-Ohayon, et al.
The Journal of General Virology|December 4, 2003
Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeysSridhar Pennathur, Aurelia A Haller, Mia MacPhail, et al.
Clinical Breast Cancer|January 31, 2025
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical TrialsDario Trapani, Qingchun Jin, Kathy D Miller, et al.
Child and Adolescent Psychiatry and Mental Health|June 20, 2024
Acute response to the October 7th hostage release: rapid development and evaluation of the novel ReSPOND protocol implementation within a children's hospitalNaama de la Fontaine, Tamar Silberg, Jörg M Fegert, et al.
The Journal of Infectious Diseases|March 5, 2005
A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancyDavid P Greenberg, Robert E Walker, Min-Shi Lee, et al.
British Journal of Haematology|September 4, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinibPreetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, et al.
The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2017
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized TherapyLeo Zhang, Krystle Nomie, Hui Zhang, et al.
Blood Advances|March 20, 2020
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCLPreetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, et al.
Pageof 11